These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25074674)

  • 21. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
    Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
    Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure.
    Noveanu M; Breidthardt T; Potocki M; Reichlin T; Twerenbold R; Uthoff H; Socrates T; Arenja N; Reiter M; Meissner J; Heinisch C; Stalder S; Mueller C
    Crit Care; 2011; 15(1):R1. PubMed ID: 21208408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.
    Savarese G; Trimarco B; Dellegrottaglie S; Prastaro M; Gambardella F; Rengo G; Leosco D; Perrone-Filardi P
    PLoS One; 2013; 8(3):e58287. PubMed ID: 23472172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BNP in the diagnosis and risk stratification of heart failure.
    Moe GW
    Heart Fail Monit; 2005; 4(4):116-22. PubMed ID: 16234898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
    De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.
    Porapakkham P; Porapakkham P; Zimmet H; Billah B; Krum H
    Arch Intern Med; 2010 Mar; 170(6):507-14. PubMed ID: 20308637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NT-proBNP and BNP: biomarkers for heart failure management.
    Bettencourt P
    Eur J Heart Fail; 2004 Mar; 6(3):359-63. PubMed ID: 14987589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure.
    Miller WL; Hartman KA; Grill DE; Burnett JC; Jaffe AS
    Clin Chem; 2009 Jan; 55(1):78-84. PubMed ID: 19028821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
    Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
    Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
    Januzzi JL; Rehman SU; Mohammed AA; Bhardwaj A; Barajas L; Barajas J; Kim HN; Baggish AL; Weiner RB; Chen-Tournoux A; Marshall JE; Moore SA; Carlson WD; Lewis GD; Shin J; Sullivan D; Parks K; Wang TJ; Gregory SA; Uthamalingam S; Semigran MJ
    J Am Coll Cardiol; 2011 Oct; 58(18):1881-9. PubMed ID: 22018299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease].
    Wu YR; Chen SB; Sun K; Huang MR; Zhang YQ; Chen S
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):728-32. PubMed ID: 17229370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
    J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide.
    Miller WL; Burnett JC; Hartman KA; Hodge DO; Giuliani I; Minard F; Larue C; Jaffe AS
    Clin Chim Acta; 2009 Aug; 406(1-2):119-23. PubMed ID: 19523938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care?
    Christenson RH
    Clin Chem Lab Med; 2008; 46(11):1524-32. PubMed ID: 18847367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure.
    Khanam SS; Choi E; Son JW; Lee JW; Youn YJ; Yoon J; Lee SH; Kim JY; Ahn SG; Ahn MS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ; Yoo BS
    PLoS One; 2018; 13(11):e0206380. PubMed ID: 30485284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.
    Jafri L; Kashif W; Tai J; Siddiqui I; Azam I; Shahzad H; Ghani F
    BMC Nephrol; 2013 May; 14():117. PubMed ID: 23725445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
    Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
    Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.